ClinicalTrials.gg

Program

2,4-thiazolidinedione

Also written as “Thiazolidinedione” and “Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione”.

Its studies are mostly in Diabetes Mellitus · Diabetes Mellitus, Type 2, led by 3 companies.

Furthest: phase 3, since Jun 30, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eurofarma Laboratorios10 open or runningphase 3since Jun 30, 2025Jun 30, 2025none ahead
GlaxoSmithKline10 open or runningphase 3since Jan 24, 2013Jan 24, 2013none ahead
Sanofi10 open or runningphase 3since Sep 30, 2002Sep 30, 2002none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2002First study: phase 3 study in Diabetes MellitusNew to SanofiSanofi · NCT00046462 · 240 enrolled · United States
  2. Jan 24, 2013GlaxoSmithKline’s first study: phase 3 study in Diabetes MellitusNew to GlaxoSmithKlineGlaxoSmithKline · NCT01777282 · 374 enrolled · Japan
  3. Jun 30, 2025Eurofarma Laboratorios’ first study: phase 3 study in Diabetes Mellitus, Type 2New to Eurofarma LaboratoriosEurofarma Laboratorios · NCT07057479 · Brazil

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07057479Diabetes Mellitus, Type 2 · Brazil3WithdrawnEurofarma LaboratoriosFeb 20280
NCT01777282Diabetes Mellitus · Japan3CompletedGlaxoSmithKlineJan 27, 2015374
NCT00046462Diabetes Mellitus · United States3CompletedSanofiNov 2004240

How it is read

Names in the registry

  • “Thiazolidinedione”, 2 entries
  • “Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.